Led by researchers at the University of Laval in Canada, the study found that mice with increased levels of cannabinoid ...

Cannabis interacts with our body’s endocannabinoid system, influencing mood, memory, and pain perception. While it offers ...

“Skye believes nimacimab shows potential both as a monotherapy and in combination with a GLP-1 targeted drug to address unmet needs in obesity with the potential to change weight loss standards of ...

CBD and THC, both derived from cannabis, interact differently with our bodies, leading to varied effects and potential benefits.

Montreal-based Inversago Pharma is developing a portfolio of peripherally-acting cannabinoid receptor-1 (CB1) inverse agonists, including its lead candidate INV-101, in development for the ...

Agonists of the type 1 cannabinoid receptor (CB1) show promise as alternative analgesics but are still limited by side effects and tolerance. Reporting in Nature, Rangari et al. apply computation ...

The acquisition will add SKNY-1 to Mira’s pipeline. Mira said the oral candidate is “designed to interact with cannabinoid receptors CB1 and CB2 pathways.” Interest in treating smoking and ...